title: [A meta analysis of aidi injection plus taxotere and cisplatin in the treatment of non-small cell lung cancer].
abstract: BACKGROUND
  Compared with chemotherapy, whether aidi injection can improve the patient's quality of life is not definite. The aim of this study is to evaluate the efficacy and safety of axotere plus eisplatin chemotherapy combining aidi injection for patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  We searched relevant randomized controlled trials (RCTs) from Cochrane library, Pubmed, EMBASE, CancerLit, VIP, CBM and CNKI etc. The search was finished in March 20, 2010. We traced the related references and experts in this field, besides we also communicated with other authors to obtain some certain information that has not been found. RCTs of aidi injection plus TP versus TP for advanced NSCLC were included. We evaluated the quality of these included studies and analyzed data by Cochrane Collaboration's RevMan 5.0 software.
  
  
  RESULTS
  Eleven RCTs involving 800 patients were included. meta analysis results suggested that compared with TP chemotherapy alone, the combination had a statistically significant benefit in healing efficacy (RR=1.2, 95%CI: 1.10-1.47, P=0.001) and improving quality of life (QOL) (RR=1.85, 95%Cl: 1.54-2.21, P < 0.001). Besides, the combination also had a statistically significant benefit in myelosuppression, white blood cell (WBC)(RR=0.71, 95%CI: 0.57-0.87, P=0.001) and hematoblast (RR=0.59, 95%CI: 0.40-0.87, P=0.008) and in reducing the gastroenteric reaction (RR=0.75, 95%CI: 0.58-0.98, P=0.03). But the combination had no statistically significant benefit in prevention of reducing hemoglobin (Hb) (RR=0.97, 95%CI: 0.70-1.34, P=0.85), liver function (RR=0.63, 95%CI: 0.09-1.57, P=0.18), kidney function (RR=0.42, 95%CI: 0.14-1.24, P=0.12), peripheral neuritis (RR=0.86, 95%CI: 0.56-1.32, P=0.50), and baldness (RR=0.92, 95%CI: 0.63-1.34, P=0.66).
  
  
  CONCLUSIONS
  Compared with TP chemotherapy alone, the combination can significantly improve the efficiency, QOL and myelosuppression, and reduce adverse events.
authors.affiliation: Evidence Based Medicine Center of Lanzhou University, School of Basic Medical Science of Lanzhou University, Lanzhou 730000, China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Wang
authors.forename: Xiran
authors.initials: X
authors.lastname: He
authors.forename: Jinhui
authors.initials: J
authors.lastname: Tian
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Wang
authors.forename: Peifan
authors.initials: P
authors.lastname: Ru
authors.forename: Ziliang
authors.initials: Z
authors.lastname: Ruan
authors.forename: Kehu
authors.initials: K
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D043823:Taxoids; C517300:aidi herbal drug; D000077143:Docetaxel; D002945:Cisplatin